Skip to main content

Table 6 Pathology result aided by the index ENB procedurea

From: Electromagnetic navigation bronchoscopy to access lung lesions in 1,000 subjects: first results of the prospective, multicenter NAVIGATE study

N = 910 subjects with navigation complete and tissue sample obtained

Malignant

45.8% (417/910)

 Lung cancer

40.1% (365/910)

  Non-Small Cell Lung Cancer (NSCLC)

36.4% (331/910)

   Adenocarcinoma

23.5% (214/910)

   Squamous Carcinoma

11.4% (104/910)

   Other NSCLC

1.5% (14/910)

  Small Cell Carcinoma

2.9% (26/910)

  Neuroendocrine Carcinoma

1.1% (10/910)

 Metastatic Carcinoma of Extrathoracic Origin

4.4% (40/910)

 Lymphoma

0.2% (2/910)

 Malignant Cells (unable to characterize)

0.9% (8/910)

 Other

0.3% (3/910)

Site-Reported Non-Malignant or Inconclusive Results

 Non-Malignant

40.9% (372/910)

  Normal Lung Tissue/Bronchial Epithelium

10.4% (95/910)

  Benign Non-Specific

21.9% (199/910)

   Benign Inflammation

15.3% (139/910)

   Otherb

6.7% (61/910)

  Infection

2.9% (26/910)

   Bacterial

1.8% (16/910)

   Fungal

0.9% (8/910)

   Viral

0.2% (2/910)

  Granuloma

1.4% (13/910)

  Atypical Cells

1.9% (17/910)

  Lymphocytes

1.1% (10/910)

  Organizing Pneumonia

0.8% (7/910)

  Interstitial Lung Disease

0.4% (4/910)

  Otherc

1.0% (9/910)

 Inconclusive

13.3% (121/910)

  1. Data are presented as n/N (%) or mean ± standard deviation (n) (range)
  2. Acronym: ENB electromagnetic navigation bronchoscopy
  3. aPreliminary 1-month results, to be confirmed by subsequent surgery, biopsy, or radiographic follow-up through 2 years as appropriate per clinician’s assessment of the patient’s probability of malignancy. One-month follow-up in this interim analysis is not sufficient to calculate the true negative rate or diagnostic yield
  4. bIncludes reactive bronchial cells and other nonspecific “benign” diagnoses
  5. cReported as 1 case each of: (1) fibroelastic scar, (2) squamous dysplasia, (3) squamous metaplasia, (4) radiotherapy changes, (5) blood clots post-FNA, (6) asbestos fibrosis, (7) benign metastasizing leiomyoma, (8) focally anthracotic alveolated pulmonary parenchyma, and (9) iron pill aspiration